Resistin, acute coronary syndrome and prognosis results from the AtheroGene study

Lubos, E. et al. (2007) Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis, 193(1), pp. 121-128. (doi: 10.1016/j.atherosclerosis.2006.05.039)

Abstract

<p><b>Objective</b> <br>Resistin, an adipocyte and macrophage derived cytokine, causes insulin resistance and glucose intolerance. We investigated the impact of resistin as a diagnostic marker in patients with acute coronary syndrome and its prognostic value for future cardiovascular events.</br></p> <p><b>Methods</b> <br>Resistin levels were determined in 1153 patients with stable angina (SAP), 380 patients with unstable angina, 278 patients with non-ST-elevation myocardial infarction (NSTEMI) and 111 patients with ST-elevation myocardial infarction (STEMI). All patients have been followed up for a median follow-up of 2.6 years. During follow-up, 70 patients died from cardiovascular causes.</br></p> <p><b>Results</b> <br>Compared to SAP, resistin levels (5.1 ng/mL in SAP) were elevated in patients with angina at rest (5.89 ng/mL, P = 0.001), in patients with NSTEMI (6.00 ng/mL, P < 0.001), and in patients with STEMI (5.98 ng/mL, P < 0.001). Resistin levels rose at 3–6 h after chest pain onset (5.46 ng/mL), persisted elevated among those individuals presenting between 6 and 12 h after chest pain onset (5.57 ng/mL) and peaked in individuals presenting more than 12 h after chest pain onset (5.74 ng/mL). An increase of one standard deviation of resistin levels was associated with a 1.22-fold (95% CI 1.04–1.43; P = 0.02) risk for future fatal cardiovascular events in a model adjusted for risk factors and clinical and therapeutic variables. When adjustment for renal function was applied, this association lost its statistical significance.</br></p> <p><b>Conclusions</b> <br>Resistin levels are elevated in patients presenting with unstable angina, NSTEMI and STEMI and might play a role as a diagnostic marker. In addition, systemic resistin level is moderately associated with future cardiovascular death in patients with documented coronary artery disease.</br></p>

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Messow, Dr Martina
• Authors: Lubos, E., Messow, C., Schnabel, R., Rupprecht, H.J., Espinola-Klein, C., Bickel, C., Peetz, D., Post, F., Lackner, K.J., Tiret, L., Munzel, T., and Blankenberg, S.
• Subjects: R Medicine > R Medicine (General)
• College/School: College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre; ?? 20206000 ??
• Journal Name: Atherosclerosis
• Publisher: Elsevier Ireland Ltd
• ISSN: 0021-9150
• ISSN (Online): 1879-1484
• Published Online: 30 June 2006